Background. Prediction of bloodstream infection at the time of sepsis onset allows one to make appropriate and economical management decisions.
Risk stratification at the time of disease onset allows for appropriate and economical management decisions. Among patients with infection, bacteremia portends a poor prognosis, and clinicians' ability to predict its presence is low [1, 2] .
Blood cultures are routinely performed in hospitals for patients with possible bacteremia, even when the risk is low. It is currently accepted that only ∼10%-15% of blood culture results are positive, of which 30%-50% of the results represent contaminants [3] [4] [5] .
The costs of performing and handling negative and false-positive blood culture results are significant. Bates et al. [6] reported a 20% independent increase in total hospital charges for patients with contaminated blood cultures associated with additional testing, empirical treatment, and increased hospital stay. Empirical treatment frequently entails unnecessary use of vancomycin [7] . Defining of a group of patients with a very low probability of bacteremia would reduce costs and prevent unnecessary antibiotic treatment. Alternatively, selection of a group with a high likelihood for bacteremia caused by specific pathogens may assist health care providers in choosing treatment and determining whether to perform new, costly tests. Molecular methods for rapid pathogen identification or resistance testing may be used clinically [8] , but they are likely to be costeffective only among preselected patients [9] . . The basic units of the model are pathogens (boxes) for which the probabilities are determined by site-specific risk factors (e.g., presence of a urinary catheter, place of infection acquisition, sex, and age for urinary tract infections). Pathogens cause local infections, which cause local signs or symptoms (diamonds) and systemic signs of sepsis through sepsis mediators. For simplicity, single variables are shown: 1 pathogen (Escherichia coli), 2 sites of infection (urinary tract and abdominal infections), a single sepsis mediator, and 2 sepsis signs (fever and chills). Pathogens causing infections may be found in local samples (Ecoli_urin; Ecoli_local) and in the blood. The presence of bacteria in blood may be detected in aerobic and anaerobic bottles (Ecoli_Aerob; Ecoli_Anaerob). Each CPN node represents a probability table. Additional explanation can be found in the Appendix
We developed a computerized decision support system (TREAT) based on a causal probabilistic network for diagnosis and treatment of infections among inpatients [10] [11] [12] . The network predicts the probabilities of the presence of pathogens on the basis of clinical variables available at the time treatment is initiated. It also predicts the probabilities of pathogen growth in the bloodstream and pathogen detection in blood culture bottles.
We assessed the ability of TREAT to predict bacteremia in a prospective cohort of inpatients. With use of TREAT's bacteremia prediction values, we determined thresholds to define 3 patient risk groups with increasing risks and prevalences of bacteremia. We applied the same thresholds to a second, independent, prospective cohort and assessed the prevalence of bacteremia within each of the 3 TREAT risk groups to test the stability of TREAT's means of bacteremia prediction.
METHODS

The TREAT System
The TREAT system is based on a causal probabilistic network (CPN) [10] [11] [12] . A CPN consists of a set of variables and directed links between these variables. Links reflect cause-effect relationships. The strength of an effect is modeled as a probability. The basic units of the TREAT model are pathogens. The model follows the pathogenesis of infection (figure 1). Additional explanation can be found in the Appendix.
We differentiated between universal and local probabilities. Universal probabilities do not change locally or temporally. These include sensitivities and specificities of symptoms, signs, and diagnostic tests; the probability for bacteremia given a known site of infection; and baseline prevalence of specific conditions or factors (e.g., presence of prosthetic heart valve). The probabilities for these variables were based on published systematic reviews or our own compilation of available literature. The majority of the variables in the CPN are calibrated locally; these include pathogen prevalence in the different sites of infection, pathogen prevalence for blood culture contamination, antibiotic susceptibilities, baseline prevalence of certain underlying conditions (e.g., drug abuse), etc. TREAT was calibrated to 3 hospitals using local data.
The system may be used at any decision point during the course of antibiotic therapy. The present study addressed the patient-physician encounter at the time that blood samples were drawn for culture. Input data included the patients' demographic characteristics, background conditions, devices (e.g., presence of catheter), vital signs, laboratory test results, symptoms and signs relevant to infection, and available radiological (e.g., chest radiography) and microbiological (e.g., local Gram stain) results. The system uses as much data as available; missing data are handled using locally calibrated probabilities predefined within the CPN.
Cohorts
Cohort 1. The first cohort consisted of patients included in an observational study of the TREAT system [13] . The study was conducted at 3 sites: Rabin Medical Center, Beilinson Campus (Israel), which includes 6 departments of internal medicine, for the period from July 2002 through January 2003; University Hospital of Freiburg (Germany), which includes 6 departments of internal medicine, for the period from July 2002 through January 2003; and Gemelli Hospital in Rome (Italy), which includes 3 departments of infectious diseases, for the period from March through September 2003. All patients who fulfilled inclusion criteria from whom blood samples were drawn for culture were included in the present study. The study included (1) patients whose cases fulfilled the criteria for systemic inflammatory response syndrome [14] ; (2) patients who had been prescribed antibiotics (but not for prophylaxis); (3) patients with a focus of infection; (4) patients with shock, with symptoms compatible with septic shock; (5) patients with febrile neutropenia; and (6) any other patients from whom blood samples were obtained for culture. Data were collected prospectively at the time that blood samples were obtained. Outcome data collected 30 days after the patients' recruitment included microbiological results for all studies of blood and other samples obtained from onset and up to 7 days after onset of the infectious episode, 30-day allcause mortality, and durations of fever and hospital stay.
Cohort 2. The second cohort consisted of patients included in a cluster-randomized controlled trial of the TREAT system conducted from May through November 2004 in the same hospitals [15] . This study aimed to assess the effect of use of the TREAT system on patient management. Participating wards in the 3 hospitals were randomized to intervention or control wards. The TREAT system was installed in intervention wards. Clinicians in intervention wards entered data for patients fulfilling inclusion criteria to the system and were shown TREAT's results. Results included predicted probabilities for infection overall, specific sites of infection and diagnoses, pathogens causing infection, and a recommendation regarding antibiotic treatment. In the control wards, clinicians had no access to the TREAT system. Prospective data collection continued, and local guidelines were distributed. Outcome data were collected at 30 days.
Blood Cultures
In Israel and Italy, 2 sets of blood samples were obtained for aerobic and anaerobic bottles and were processed using the Bactec 9240 (Becton Dickinson). In Italy, the BacT/ALERT 3D system (bioMérieux) was used as well. In Germany, 2-3 sets of samples (2 for aerobic bottles and 1 for an anaerobic bottle) were obtained and processed with the BacT/ALERT 3D system. Clinically significant bacteremia (referred to hereafter simply as "bacteremia") was defined by the isolation of bloodstream pathogens accompanied by systemic inflammatory response syndrome or documented focus of infection. Coagulase-negative staphylococci or aerobic gram-positive bacilli that grew in a single bottle were considered to be contaminants unless the finding was supported by clinical or other microbiological evidence of infection.
Data Analysis
Predictive performance of the system was assessed using a receiver-operating characteristics (ROC) curve. The ROC curve plots true-positive versus false-positive predictions for bacteremia, and the area under the curve is a measure of the accuracy of discrimination of the system's predictions, with significance tested against the null hypothesis of the area under the curve at 0.5.
We used the first cohort to derive thresholds for 3 TREAT bacteremia risk groups. These groups were defined by cutoff values for the probability yielded by the TREAT system for bacteremia. We applied the same cutoff values to the second cohort and assessed the true rate of bacteremia in each TREAT risk group. Differences between risk groups were assessed using a x 2 test. Both studies were approved by the research ethics committees at each site.
RESULTS
Cohorts
Cohort 1. The first cohort included 790 patients from the 3 sites (table 1) . Infections were most commonly acquired in the community (72.7%). The most common site of infection was the respiratory tract (28.6%), followed by the urinary tract (15.3%). The all-cause 30-day mortality rate was 11.4%. In- (table 1) . Infections were microbiologically documented in 27.5% of patients, and bacteremia was detected in 13.5%. More infections were caused by gram-negative bacteria than in the first cohort. Among all patients in the second cohort, the ROC curve for the probability of bacteremia determined using the TREAT system was similar to that generated in the derivation set, yielding an area under the curve of 0.70 (95% CI, 0.67-0.73;
). P ! .001 We applied TREAT's bacteremia probability threshold values from the first cohort to the second cohort (table 2). The percentage of patients included in each risk group remained stable. Bacteremia rates in the low-, intermediate-, and high-risk groups were 1.3%, 13.2%, and 28.1%, respectively, and were well within the ranges defined by cohort 1.
Similar to the first cohort, blood culture contamination rates were higher than the rate of true bacteremia in the low-risk group (4 [1.3%] of 300 patients vs. 9 [3.0%] of 300 patients). The positive predictive values for growth in blood cultures remained similar at 30.8% in the newly defined low-risk group, compared with 83.3% in the high-risk group.
Risk Stratification in the Different Testing Sites
The 3 sites cater to different populations (table 3) . Patients in Italy were younger, and the prevalence of HIV infection was high. In Israel, most patients were elderly, infections were acquired mostly in the community or nursing homes, chronic underlying conditions were common, and a high percentage of patients had no documented infection. In Germany, more cases of nosocomial and intensive care unit-acquired infections were present. The rate of bacteremia was lowest among patients in Italy (8.9%), and it was highest in Germany (16.9%). The mortality rate was higher in Israel and Germany than in Italy.
The model's performance was separately assessed in each site (table 4) . Bacteremia among patients classified to the low-risk group occurred in 1 (1.3%) of 77 patients in Italy, 5 (1.7%) of 290 patients in Israel, and 1 (1.8%) of 56 patients in Ger-many. The rate of bacteremia among patients in risk group 3 ranged from 26% to 30% at the 3 sites. Risk stratification was stable in both cohorts (data not shown). The all-cause mortality rate was higher in the high-risk group than in the low-risk group at the 3 sites (in Italy, 14 
Analysis of Bacteremic Patients in the Low-Risk Group
Overall, there were 7 bacteremic patients in the lowest-risk groups (table 5). The temperature was р38.0ЊC in all patients but 1. No other signs of sepsis were present, except for hypotension in a single patient with congestive heart failure. All localizing symptoms and signs were absent in 5 patients.
DISCUSSION
In the present study, we tested the ability of TREAT, a computerized decision support system, to predict the presence of bacteremia. The system was tested at the time when blood samples were obtained for cultures, using simple variables available to the clinician at this time. We used a first cohort to derive 3 bacteremia risk groups, in which the prevalence of bacteremia ranged from 2.4% for the low-risk group to 29.9% for the high-risk group. This classification was applied to a second, independent cohort and demonstrated good performance: 1.3% of patients had bacteremia in the low-risk group, and 28.1% had it in the high-risk group. The percentage of patients in the low-and high-risk groups remained stable. The risk groups were significantly associated with the risk of death. The ROC curves for both cohorts were statistically significant and demonstrated stable discriminative power to detect bacteremia.
Several features of our study merit emphasis. The study was conducted in 3 different hospitals in Israel, Germany, and Italy. The patient populations served by these hospitals are heterogeneous. The discriminative ability of the model was stable in the 3 sites. In the second cohort, data were entered into the system by clinicians using the system in real time as part of an interventional trial of the system. Performance was remarkably stable in the interventional cohort, as well as in the observational cohort.
Several limitations of our study warrant consideration. First, among patients classified as low risk, there were 7 cases of bacteremia. Review of the data revealed that these patients did not have signs of sepsis or local findings. Their cases may represent true cases of bacteremia without sepsis. Alternatively, these cases may represent a problem in the representation of time in the system: variables used by the model (mainly fever and other signs of sepsis) change with time. We asked clinicians to enter variables as available at the time of admission; this could lead to misrepresentation of the overall sepsis episode.
Second, no electronic patient files were used at our testing sites, and we did not try to integrate TREAT into one. Finally, we did not assess the effect of TREAT's bacteremia prediction on clinician's performance or patient-related outcomes. Performance of decision-support systems should be measured by these outcomes [16] .
Several clinical models to predict bacteremia have been developed [2, 5, [17] [18] [19] [20] . They have not entered wide clinical use [21] . A major problem observed with previous models was their degradation when applied to populations different than those used for model development [20, 22, 23] . Specifically, when transferred to other hospitals, the models could not define a group of patients with a risk low enough as not to necessitate the performance of blood cultures. Otherwise, the low-or highrisk groups were too small to be clinically significant. Bates et al. [5] developed a model that performed well in the derivation and validation cohorts in the hospital where it was developed, defining a low-risk group with a 1%-2% rate of true bacteremia and a high-risk group with a 14%-16% rate of true bacteremia. This model was tested in other hospitals [22] [23] [24] . In one hospital, the percentage of bacteremia cases in the low-risk group increased to 13%-15%, and in another, it increased to 6%-15% [23, 24] . Several variables included in the original model were not relevant to the newly tested populations (e.g., drug abuse). In a third hospital, the model successfully defined lowand high-risk groups, with prevalences of bacteremia of 3% and 16%, respectively, but discrimination in the intermediateprobability groups deteriorated [22] . Leibovici et al. [2] developed a clinical rule that was validated locally and defined risk groups that were highly discriminative with regard to bacteremia and mortality. When tested at another site, the prevalence of bacteremia in the low-risk group increased from 1%-5% in the original cohort to 10%-12% in the new cohort. The high-risk group maintained its predictive ability, but it included only 4%-5% of all patients in the new cohort [23] . More recently, Bates et al. [17] used a large, multicenter cohort of patients to derive and validate clinical prediction rules for bacteremia using a comprehensive set of variables. Overall, the prevalence of bacteremia in the cohort was 32%. The lowest prevalence of bacteremia that could be defined in the low-risk group was 14%-15%. The high-risk group was defined by a bacteremia prevalence of 61%-64%, but this group consisted only of 9%-10% of all patients.
With use of the TREAT system, we showed consistent performance in 3 different hospitals. Both the prevalence of bacteremia in the low-and high-risk groups, as well as the proportion of patients included in these groups (∼35% of all patients), remained stable. There are several advantages to our system and to the use of a causal probabilistic network over previous models, as has been recently reviewed elsewhere [25] . The pathophysiology underlying the development and detec-tion of bacteremia is clear. Thus, the graphical structure of the network-the most important condition for its accurate performance-is accurate [26] . The CPN, as opposed to a multivariate model, uses many variables. The graphical structure accounts for the independence or the relationships between these variables, enabling a more complex model. We carefully separated universal and local factors. Values for variables that change from place to place or over time were calibrated in the system. The CPN uses these locally calibrated baseline probabilities for missing data. Finally, decision rules may encumber clinicians, whereas TREAT is a computerized system. Its performance, when used by clinicians, was similar to that in the observational cohort. However, the 3 recruitment sites were university hospitals, and few intensive care unit or surgical patients were included. Performance with missing data depends on the quality of local calibration. The model must be evaluated in other hospitals and settings.
Implications for practice. The TREAT computerized decision-support system can improve selection of patients for performing and processing blood cultures. At the time that blood samples are drawn for culture, identification of a patients with a very low risk of bacteremia may serve to withhold blood cultures, thus avoiding the costs of samples that would yield negative results, additional testing, and treatment of patients whose cultures reveal contaminants [6] . TREAT identified a group of patients with a low risk of bacteremia (!2.5%), consisting of 15% of all patients from whom clinicians elected to draw blood samples for culture. Conversely, at this time, TREAT identified a high-risk group (risk of bacteremia, 125%) with a similar number of patients. The system can thus select candidates for a new treatment modality or triage patients for molecular analysis of blood samples.
When growth is detected in a culture bottle, knowledge regarding the clinical significance of this growth may permit judicious microbiological evaluation. TREAT's discriminative power permitted a stable prediction of the clinical significance of growth in blood cultures, defining a high-risk group in which 83% of positive blood culture results were clinically significant.
Implications for additional research. The effect of the system's predictions and risk classification on physicians' performance and patient outcomes must be evaluated. Interaction between the system and clinicians should be assessed outside the situation of a trial, preferably incorporating TREAT into an electronic patient file.
In summary, TREAT, a computerized decision-support system, provides good prognostic ability to predict bacteremia. The system may serve to select patients with low risk for bacteremia, for whom blood cultures may not be needed, and patients with a high likelihood for bacteremia, for whom further evaluation and directed treatment are essential. hav, Erez Skapa, and Abigail Fraser. Prof. Henrik C. Schonheyder contributed to the basic concepts of the TREAT system. Financial support. European Union fifth framework, Information Society Technologies (contract IST-9999-11459).
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APPENDIX THE TREAT SYSTEM
The TREAT system is based on a causal probabilistic network (figure 1). A causal probabilistic network includes variables (nodes) and links (arrows). The links between the variables represent causality. The variables are presented as probabilities. The basic units of the TREAT model are pathogens (boxes) for which the probabilities are determined by site-specific risk factors. The probability table for "E_coli_uti" is shown. The highlighted figure in the table represents the probability for "no" Escherichia coli urinary tract infection in a woman in the community without a urinary catheter. The table is a conditional probability table, because its probabilities are dependent on the state of the parent node(s) ( , , and catheter p no sex p female place of acquisition). From pathogens onward, the infection domain is modeled following disease pathogenesis. All pathogens contributing to a single site of infection are joined to the site node (e.g., urinary tract infection). The presence of infection at the site is responsible for local signs or symptoms (diamonds), findings on imaging or other diagnostic tests (not shown in the figure), and systemic signs of sepsis through sepsis mediators (e.g., fever and chills). Pathogens causing infections may be found in local samples (Ecoli_urin; Ecoli_local) and in the blood.
In the TREAT system, we modeled 11 sites of infection (e.g., abdominal) and 34 different diagnoses (e.g., appendicitis or diverticulitis) representing common community-acquired and nosocomial infections. The system covers 155 pathogens and includes 214 other clinical variables and 18000 nodes. Clinical variables in the model include demographic variables, background diseases and conditions, signs and symptom of sepsis and local infection, microbiological data, findings from radiography other specific diagnostic tests (such as serologic or direct antigen tests), and previous antibiotic treatment. The probabilities for all variables are predefined within the network on the basis of extensive literature reviews and local data where appropriate.
An explicit part of the system is a calibration component, updating the probabilities within the network to different locations and temporal changes. We predefined "local variables" in the model that will necessitate secular adjustment. Thus, the probability of dysuria given pyelonephritis is constant, whereas the probability of E. coli causing urinary tract infection in the intensive care unit changes. "Local variables" are placed in TREAT calibration databases, allowing for a semiautomatic calibration of the complete system.
Building the system progresses from pathogens to signs and symptoms. Data entry occurs in the opposite direction: information regarding symptoms and signs (e.g., "
" and fever p 38 "flank ") is entered to the system, and pathogen pain p yes probabilities are recalculated, adjusted to the data which were entered to the system. In clinical practice, data available at the time the patient is seen are transferred from TREAT's user interface to the causal probabilistic network. All known data are used to set the variables in the causal probabilistic network to the known state (e.g., dysuria set to "yes"). Missing data are handled naturally, using preexisting probabilities present in the network. The system's output includes a diagnosis read from the site nodes (e.g., urinary tract infection node), pathogen distribution (read from individual pathogen nodes), and the probability for bacteremia (read from the aerobe and anaerobe blood culture nodes). The TREAT system uses the pathogen predictions in the network to recommend antibiotic treatment.
